International HTA Experience with Targeted Therapy Approvals for Lung Cancer

Maraiki, Fatma; Byrnes, Joshua; Tuffaha, Haitham; Hinder, Markus

doi:10.1007/s41669-018-0088-x

Cited by 5 publications

(2 citation statements)

References 8 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Future efforts, therefore, should be directed toward deriving a country-specific CET for Jordan based on the opportunity cost by considering marginal health spending and health gains. It is also essential to develop a national HTA framework that is responsive to stakeholders’ needs in an equitable way [ 28 , 29 ]. Such a framework should be supported by practical but rigorous evaluation methods and transparent reporting and governance to enhance the uptake of HTA recommendations and their implementation in practice.…”

Section: Discussionmentioning

confidence: 99%

Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan

Treish

Rabayah

Jaddoua

et al. 2021

PharmacoEconomics Open

View full text Add to dashboard Cite

Rising prices of novel cancer medications are increasing the economic burden from cancer in Jordan, risking the ability of cancer patients to access lifesaving and life-extending treatments. Furthermore, in the absence of a national health technology assessment (HTA) framework, medication prices in Jordan are set based on manufacturers’ pricing considerations and not a value proposition. In response to these challenges, King Hussein Cancer Center (KHCC), the de facto national cancer institute, developed a first-in-country, cancer-specific, cost-effectiveness threshold (CET) to aid institutional decision makers in approving only cost-effective medications. Over the past 10 years, cost-effectiveness analyses based on this CET have led to the introduction of > 70% of requested novel cancer medications after manufacturers agreed to lower prices, beyond registration prices, to meet the CET. Future work is warranted to empirically derive a CET for Jordan to better guide reimbursement decisions. Supplementary Information The online version contains supplementary material available at 10.1007/s41669-021-00293-4.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan

Treish

Rabayah

Jaddoua

et al. 2021

PharmacoEconomics Open

View full text Add to dashboard Cite

show abstract

“…Few studies focus speci cally on time to entry of new medicines in Europe and its determinants and these studies mainly focus on oncology medicines [9,10] since cancer is a major contributor to the global burden of disease. To the best of our knowledge, in Greece, a country where the HTA process was lately introduced, such data is completely lacking.…”

Section: Introductionmentioning

confidence: 99%

Time to Patients’ Access to New Medicines in Greece: Evaluation of Health Technology Assessment (HTA) Process from July 2018 until January 2021.

Kourlaba¹,

Beletsi

2021

Preprint

View full text Add to dashboard Cite

Background: To present the outcome of the Health Technology Assessment (HTA) process in Greece from its onset back in July 2018 till January 2021 and to quantify the median time from marketing authorization (MA) to listing especially for new medicines. Methods: All products included in the reimbursement positive list from July 2018 to January 2021, were identified through the relevant Ministerial Decisions (MDs) posted on the website of the Ministry of Health (MoH) and the Positive Reimbursement Lists issued this period. The following information were collected for these medicines: date that MDs and Positive Reimbursement lists were issued, the legal basis of the initial MA, the MA date, the date of price registration, and the type of the HTA application. The time from MA to listing was calculated. Results: During the study period, 38 MDs were issued from which 35 (92%) were positive and resulted in the inclusion of 318 medicines and 3 (8%) were negatives that excluded 6 medicines. Focusing on new medicines, the median time from MA to listing was found to be 30 months with an interquartile range of 22 to 39 months. This time was statistically significantly shortened for FDC [19.3 (13-35) months], compared to biosimilars [26 (22-35) months, p=0.09] and on patent [38.5 (29-44) months, p=0.008]. For new generics, the corresponding median time was 22 (IQR: 12.5-31) months, statistically significantly lower than that of new medicines (p=0.028). Focusing on the four most common therapeutics areas, the median (IQR) time from MA to listing for new medicines was 28.3 (24.9–32.9) months and 34.9 (21.9-41.1) months, for oncologic and immunosuppressants (p=0.136), respectively, while on the field of cardiovascular and CNS there was no reimbursement of new active substances during the study period. Conclusions: This study showed that it takes a long time for Greek patients to get access to newly registered medicines. Given that the delay in access might result in potential loss of many life years, actions should be taken by policy makers to speed up patients access to new and innovative medicines.

show abstract

Low listing success rate for novel lung cancer therapies

2018

PharmacoEcon Outcomes News

View full text Add to dashboard Cite

International HTA Experience with Targeted Therapy Approvals for Lung Cancer

Abstract: This study demonstrated a low listing success rate for novel lung therapies internationally within different HTA jurisdictions. Major uncertainties that are resistant to available solutions seem to be common across different countries; thus, international solutions would be beneficial.

Cited by 5 publications

References 8 publications

Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan

Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan

Time to Patients’ Access to New Medicines in Greece: Evaluation of Health Technology Assessment (HTA) Process from July 2018 until January 2021.

Low listing success rate for novel lung cancer therapies

Contact Info

Product

Resources

About